Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $10.8 million for a MS vaccine.
If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is -$12,000. A negative value represents a saving in costs in addition to a saving in QALYs. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is -$11,000.
Anderson DW, Ellenberg JH, Leventhal CM, et al. Revised Estimate of the Prevalence of Multiple Sclerosis in the United States. Annals of Neurology 1992; 31:333–336.
Koch-Henriksen N. Incidence of Multiple Sclerosis in Denmark 1948–1982: A Descriptive Nationwide Study. Neuroepidemiology 1992; 11:1–10.
Miller CM, Hens M. Multiple Sclerosis: A Literature Review. Journal of Neuroscience Nursing 1993; 25:174–179.
Multiple Sclerosis Foundation. 1997. Multiple Sclerosis Statistics. URL http://www.msfacts.org/stats.htm (accessed September 26, 1997).
Warren S, Warren KG. Prevalence, Incidence, and Characteristics of Multiple Sclerosis in Westlock County, Alberta, Canada. Neurology 1993; 43:1760–1763.